After leaving Apple, Tim joined a prominent horticultural company as Media and Marketing Manager. While in this role Tim was responsible for marketing strategies and customer experience as well as business development.
Prior to moving to Australia in 2015, Tim was prominently involved in the UK medical cannabis initiative, working with some of the industry’s global leaders and has acquired a comprehensive cannabis industry knowledge-set and network base.
Tim has worked tirelessly to innovate and progress sensible approaches to cannabis legislation across Europe. This has led to an applicable and practical knowledge of the cannabis industry globally as well as a wealth of experience in medical cannabis and its relating nuances.
As Founder and Chief Executive Officer for Delta Tetra Consultancy, Tim is responsible for the daily management of Delta Tetra.
Hamish has a vast knowledge of the regulated cannabis markets with a specialization in botanical extraction through cGMP certification. Moreover, with personal and professional connections to the overseas medical cannabis markets, Hamish possesses a knowledgeable data base of the regulated cannabis industry and its best business practices.
Since joining Delta Tetra in late 2016, Hamish has brought a wealth of experience regarding operating commercial scale medical cannabis businesses as well as the astute financial & operational oversight required in a new and developing industry.
As Co-Founder and Chief Operations Officer for Delta Tetra Consultancy, Hamish is responsible for all operations at Delta Tetra.
Chris is a motivated entrepreneur, business leader and visionary. Arriving with a wealth of cannabis specific corporate experience, with an emphasis on commercial development, strategy and deal flow, Delta Tetra is excited to have added a proven grassroots talent to our ranks.
As the founder of Leafcann, Chris has demonstrated an exemplary track record for opportunity identification and deal flow – a key skill set for any budding start-up or business. Chris offers a practical understanding of strategy and operations specifically cultivated under Australian regulations.
Chris’s focus at Delta Tetra is to develop and orchestrate both domestic and international supporting partners. The Delta Tetra BDM role has been tasked with identifying industry leading innovation and best practices, with the express purpose of tailoring solutions for Australia’s medical cannabis groups.
Chris is responsible for strategic partnerships and business development at Delta Tetra.
Janelle possesses an extensive background in Medical Cannabis regulations, complementary medicine and medical device registration with a strong approach to quality auditing.
Janelle’s longstanding experience has led her to be a quick thinker with excellent communication skills, coupled with her unparalleled industry knowledge – this makes Janelle one of Australia leading regulatory & QA specialists.
Janelle stands alone when it comes to her knowledge and experience with the ODC & TGA. This is demonstrated through Janelle’s nuanced cannabis specific technical document writing skills – the tailored development of relevant Standard Operating Procedure making up the background of any compliant outfit.
Janelle is responsible for Regulatory Affairs and Quality Assurance as well as technical document development, at Delta Tetra.
Gabby has enjoyed a successful career as a within the financial sector as a mortgage broker & equity release specialist.
Utilising her wealth of experience with client management and a focus on driving results through customer service, Gabby ensures our clients have a consistent resource throughout the duration of their journey with Delta Tetra.
Gabby’s key focus at Delta Tetra is to guide all clients throughout the licensing process and beyond, ensuring that client needs are affirmed and supported in reaching their individual goals within the cannabis industry.
Gabby is responsible for daily client care and customer relations at Delta Tetra.
A proven entrepreneurial leader with a track record of delivering business growth through strong customer and commercial relationships, Zvi is an experienced M & A Professional and Corporate Strategist. With an eye for sourcing deals on a global stage, Zvi has a passion for the cannabis industry and has played a keen involvement for the previous 3 years.
Zvi has raised upwards of $50M over the past 10 years and has been instrumental in the support the Australian cannabis sector through various corporate strategy roles, fundraising & financing and commercialization.
Zvi is also a co-founder of Epicentre Property Solutions and Assets (EPSA), founder of Visage Capital, – providing corporate advisory and specialist fund raising solutions to these groups as well driving the customer acquisition and M&A functions of EPSA.
Div has over 20 years of experience in Australian and global pharmaceutical markets, project management, regulatory compliance, quality assurance, as well as analytical and technology transfer operations.
Div interests extend into development and registration of pharmaceuticals and cannabis products.
He has a successful history of speeding up drug development and approval of pharmaceutical products through his comprehensive understanding of the drug development and registration process from bench to commercialisation. His extensive knowledge of CMC documentation has allowed for seamless preparation of drug product TMFs for TGA submission, DMFs and INDs for US FDA fillings.
One of Div’s major achievements has been the successful management, scale up operations and regulatory compliance of large-scale international CBD (cannabidiol) projects.
He has a wealth of experience in preparing licensing and Import/Export Application for cannabis, synthetic CBD API, CBD/THC oil, CBD flower for managing CBD projects.
Div has significant experience in preparation and submission of ODC cultivation and manufacturing licenses as well as developing full cGMP systems for cannabis businesses.
Internationally, Div has led international inter-company technology transfer in North America, Europe and the Asia Pacific. Div’s experience in technical transfer of new products and processes from bench top to pilot-scale has facilitated Australian and US clients to supply products for clinical trials and commercial supply.
He has led the production of commercial products and clinical trial materials in a variety of dosage forms in TGA and FDA approved facilities.
Div is responsible for all Regulatory Compliance and Quality Assurance at Delta Tetra